Effects of the combination of exercise (wheel running) and atomoxetine on cocaine-seeking behavior in rats
0
Citation
0
Reference
10
Related Paper
Keywords:
Wheel running
Atomoxetine is a novel, non-stimulant, highly selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention deficit/hyperactivity disorder (ADHD). Data from clinical trials show it to be well tolerated and effective in the treatment of ADHD in children, adolescents, and adults. Improvements were seen not only in core symptoms of ADHD, but also in broader social and family functioning and self esteem. Once-daily dosing of atomoxetine has been shown to be effective in providing continuous symptom relief. Atomoxetine does not appear to have abuse potential and is associated with a benign side effect profile. The development of atomoxetine thus represents an important advance in the pharmacological management of ADHD.
Stimulant
Atomoxetine hydrochloride
Cite
Citations (59)
Stimulant
Atomoxetine hydrochloride
Animal model
Cite
Citations (5)
This poster presents efficacy, safety/tolerability data for atomoxetine in the treatment of adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Atomoxetine is a nonstimulant medication recently approved in the US as a treatment for ADHD in children, adolescents and adults.
Tolerability
Cite
Citations (0)
Atomoxetine (Strattera™, Eli Lilly & Co.) is a highly selective noradrenaline reuptake inhibitor and the first nonstimulant medication to be approved for the treatment of attention deficit hyperactivity disorder. Currently, nine published clinical trials have documented the safety and efficacy of atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder and data presented throughout the past year at national scientific meetings has further addressed its utility. This article reviews the available information on atomoxetine, accompanied by a discussion of its clinical use.
Atomoxetine hydrochloride
Cite
Citations (21)
Atomoxetine as a nonstimulant medicine was approved by the Chinese Food an Drug Administration and provide a new selection of treatment drugs for attention deficit hyperactivity disorder(ADHD).Tomoxetine is a nor-adrenaline transmitter reuptake inhibitor which can selectively inhibit synapsis noradrenaline transport protein,strengthen noradrenaline's resupination effect,and increase noradrenaline's activity released by synaptic cleft to improve the symp-toms of the ADHD patients.Compared with methylphenidate,atomoxetine does not affect the concentration of the neuro-transmitter dopamine and does not induce or increase the Tourettes' syndrome,therefore atomoxetine is more suitable to treat ADHD together with Tourettes' syndrome.In this article the treatment of atomoxetine for ADHD,including the indi-cations,dosage as well as adverse reactions and efficacy assessment are reviewed.
Atomoxetine hydrochloride
Guanfacine
Reuptake
Cite
Citations (0)
Background: Clinicians obtain critical prescribing knowledge from clinical papers and review articles. This is the first published systematic review of clinical atomoxetine data covering 2009–2011. Objective: We aim to update clinicians on current clinical atomoxetine data with specific reference to time of onset of efficacy and maximal efficacy. These data may allow critical analysis of comparative efficacy between atomoxetine and stimulant medications. Methods: A formal systematic review of atomoxetine data from January 2009–June 2011 was conducted. The search term used was “atomoxetine” in the English language. The search yielded 747 citations from which 106 are clinical data. This paper includes clinical efficacy and safety data and excludes quality-of-life and review papers. Results: Atomoxetine has an onset of action within 4 weeks (possibly within 1 week in subsequent responders) but requires at least 12 weeks for full response to be demonstrated. Treatment-naïve cohorts (6–12 weeks) report effect sizes of 0.6–1.3. Using minimum 6-week clinical trial criteria, atomoxetine may demonstrate similar efficacy to methylphenidate comparing reduction in core ADHD symptoms in meta-analysis, although the diversity of the data makes interpretation complex. From epidemiological databases, cardiovascular and suicide-related events were similar to those seen in patients taking methylphenidate. Conclusions: Incremental response time to atomoxetine should be considered in the design of future comparative efficacy trials.
Atomoxetine hydrochloride
Stimulant
Cite
Citations (71)
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel GellerClinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, USAObjective: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD).Methods: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or adolescent ADHD.Results: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short- and longer-term efficacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine's therapeutic potential for other psychiatric conditions. Short- and longer-term safety and tolerability continue to be reported.Conclusions: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine's evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity.Keywords: ADHD, atomoxetine, pediatric
Tolerability
Atomoxetine hydrochloride
Cite
Citations (56)
Attention deficit hyperactivity disorder (ADHD) is a common chronic condition with childhood onset that can continue into adulthood. Medication is a fundamental element in the management of this disorder. Atomoxetine is the newest nonstimulant medication approved by the United States Food and Drug Administration (FDA) for the treatment of ADHD. It is the only nonstimulant medication approved by the FDA for treatment of adult ADHD. Atomoxetine is a norepinephrine reuptake inhibitor that selectively inhibits the presynaptic norepinephrine transporter. A growing body of literature supports the use of atomoxetine both in children and adults with ADHD. This paper summarizes information from the literature about atomoxetine, including pharmacokinetics, pharmacodynamics, clinical trials, dosing, and side-effects.
Norepinephrine transporter
Atomoxetine hydrochloride
Cite
Citations (38)